Researchers at The Rockefeller University are testing the safety of a new investigational antibody against chronic hepatitis B. Hepatitis B virus (HBV) remains a major global health problem with an estimated 257 million people living with the infection worldwide. HBV medications can reduce HBV to very low levels in the blood and parHally repair the immune system (the system that helps your body respond to diseases).
The purpose of this research study is to evaluate the safety and tolerability of intravenous (through a vein in your arm) infusions of a new drug.
You may be eligible if you:
Are between the ages of 18 and 70
Have a chronic hepatitis B infetion and are currently on antiviral treatment
Do not have HIV or hepatitis C